| Not Yet Recruiting | A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Ce Systemic Sclerosis | Phase 3 | 2026-04-30 |
| Recruiting | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Lymphoma | Phase 2 | 2025-11-06 |
| Recruiting | A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmu Refractory Autoimmune Diseases | Phase 1 | 2025-09-04 |
| Recruiting | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Lupus Erythematosus, Systemic, Lupus Nephritis | Phase 2 | 2025-07-14 |
| Recruiting | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With R Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | 2025-03-12 |
| Recruiting | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleuc Follicular Lymphoma | — | 2025-02-04 |
| Recruiting | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated W Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | — | 2025-02-04 |
| Recruiting | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Mantle Cell Lymphoma (MCL) | — | 2025-02-04 |
| Withdrawn | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed o Relapsed or Refractory Follicular Lymphoma | Phase 3 | 2024-03-29 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relap Multiple Sclerosis, Myasthenia Gravis | Phase 1 | 2024-03-28 |
| Recruiting | Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Multiple Myeloma | Phase 2 | 2024-03-21 |
| Recruiting | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in N Multiple Myeloma | Phase 1 | 2024-02-22 |
| Recruiting | A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Relapsed and/or Refractory Multiple Myeloma | Phase 1 | 2024-01-23 |
| Withdrawn | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adu Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | 2024-01-16 |
| Recruiting | A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Dise Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis | Phase 1 | 2023-09-13 |